Fennec Pharmaceuticals Inc. (FENC) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Fennec Pharmaceuticals Inc. (FENC) Healthcare & Pipeline Overview

Fennec Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company specializing in therapies for pediatric cancer, with a focus on preventing platinum-induced ototoxicity. Their lead product, PEDMARK, represents a potential advancement in supportive care for young cancer patients undergoing chemotherapy, addressing a significant unmet medical need within the healthcare sector.

What Is the Investment Thesis for FENC?

Fennec Pharmaceuticals Inc. presents a focused investment opportunity centered on PEDMARK, its lead product candidate targeting platinum-induced ototoxicity in pediatric cancer patients. With a gross margin of 91.5%, successful commercialization of PEDMARK could drive significant revenue growth. Key catalysts include potential regulatory approvals and expansion into new markets. The company's beta of 0.93 suggests moderate volatility relative to the market. However, the company operates with a negative profit margin of -22.7%, indicating ongoing reliance on external funding. The investment thesis hinges on PEDMARK's ability to secure regulatory approval and achieve market penetration, addressing a critical unmet need in pediatric oncology and driving long-term shareholder value.

Based on FMP financials and quantitative analysis

FENC Key Highlights

• PEDMARK targets a significant unmet need: prevention of platinum-induced ototoxicity in pediatric cancer patients.
• Gross margin of 91.5% indicates strong potential profitability upon commercialization.
• Market capitalization of $289M reflects the company's current valuation and growth potential.
• Beta of 0.93 suggests moderate volatility compared to the overall market.
• Lean operational structure with 32 employees allows for focused execution and cost management.

Who Are FENC's Competitors?

FENC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are FENC's Key Strengths?

• Focus on a specific unmet need in pediatric oncology.
• Promising clinical data for PEDMARK.
• Potential for regulatory exclusivity.
• Experienced management team.

What Are FENC's Weaknesses?

• Reliance on a single product candidate (PEDMARK).
• Limited financial resources.
• Dependence on regulatory approval.
• Competition from other supportive care products.

What Could Drive FENC Stock Higher?

• Potential regulatory approval of PEDMARK in the United States and Europe (2026).
• Continued clinical development of PEDMARK for new indications or formulations.
• Expansion of commercialization efforts in key markets.

What Are the Key Risks for FENC?

• Negative return on equity (-55.1%) — the business is not currently generating profit on shareholder capital.
• Failure to obtain regulatory approval for PEDMARK.
• Competition from other supportive care products.
• Dependence on external funding to support operations.
• Product liability claims.

What Are the Growth Opportunities for FENC?

• Expansion into new geographic markets: PEDMARK has the potential to expand beyond its initial target markets, such as the United States and Europe, into other regions with significant pediatric cancer populations. This geographic expansion could significantly increase the addressable market for PEDMARK, driving revenue growth and market share. Timeline: 2027-2029. Market Size: Global pediatric oncology market.
• Development of new formulations or indications: Fennec could explore new formulations of PEDMARK or investigate its potential application in preventing ototoxicity associated with other chemotherapy agents. This could broaden the product's utility and address a wider range of patients undergoing cancer treatment. Timeline: 2028-2030. Market Size: Expanded oncology supportive care market.
• Strategic partnerships and collaborations: Collaborating with other pharmaceutical companies or research institutions could accelerate the development and commercialization of PEDMARK or other pipeline candidates. These partnerships could provide access to new technologies, expertise, and resources, enhancing Fennec's competitive position. Timeline: Ongoing. Market Size: Varies depending on the specific partnership.
• Lifecycle management strategies: Implementing lifecycle management strategies, such as patent extensions or the development of new dosage forms, could extend the market exclusivity of PEDMARK and maximize its revenue potential. These strategies could protect the product from generic competition and maintain its market leadership position. Timeline: Ongoing. Market Size: PEDMARK's existing market.
• Acquisition of complementary assets or technologies: Fennec could acquire complementary assets or technologies that align with its focus on pediatric oncology and supportive care. This could expand the company's product portfolio, enhance its research and development capabilities, and create synergies that drive long-term growth. Timeline: Opportunistic. Market Size: Varies depending on the specific acquisition.

What Opportunities Does FENC Have?

• Expansion into new geographic markets.
• Development of new formulations or indications.
• Strategic partnerships and collaborations.
• Lifecycle management strategies.

What Threats Does FENC Face?

• Failure to obtain regulatory approval.
• Competition from generic versions of sodium thiosulfate.
• Changes in clinical practice guidelines.
• Product liability claims.

What Are FENC's Competitive Advantages?

• Patent protection for PEDMARK and its formulation.
• Regulatory exclusivity upon approval (e.g., orphan drug designation).
• Specialized expertise in pediatric oncology and supportive care.
• First-mover advantage in the prevention of platinum-induced ototoxicity.

What Does FENC Do?

Fennec Pharmaceuticals Inc., founded in 1996 and headquartered in Research Triangle Park, North Carolina, is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for pediatric oncology. Originally incorporated as Adherex Technologies Inc., the company rebranded as Fennec Pharmaceuticals Inc. in September 2014 to reflect its refined focus on addressing critical needs in pediatric cancer care. The company's primary focus is the development of PEDMARK, a novel formulation of sodium thiosulfate designed to prevent ototoxicity (hearing loss) induced by platinum-based chemotherapy agents, a common and debilitating side effect in children undergoing treatment for various cancers. PEDMARK represents a significant advancement in supportive care, aiming to improve the quality of life for young cancer survivors. Fennec's commitment lies in bringing innovative solutions to market that mitigate the adverse effects of cancer treatment in children, thereby enhancing their long-term health and well-being. The company operates with a lean structure of 32 employees, emphasizing efficiency and focused execution in its clinical development and regulatory efforts.

What Products and Services Does FENC Offer?

• Develops PEDMARK, a formulation of sodium thiosulfate.
• Focuses on preventing platinum-induced ototoxicity in pediatric cancer patients.
• Conducts clinical trials to evaluate the safety and efficacy of PEDMARK.
• Seeks regulatory approval for PEDMARK from health authorities.
• Prepares for the commercialization of PEDMARK upon regulatory approval.
• Engages in research and development activities to expand its product pipeline.

How Does FENC Make Money?

• Develops and seeks regulatory approval for pharmaceutical products.
• Focuses on a specific therapeutic area (pediatric oncology).
• Aims to commercialize approved products through sales and marketing efforts.
• Potentially out-licenses or partners for commercialization in certain territories.

What Industry Does FENC Operate In?

Fennec Pharmaceuticals Inc. operates within the biotechnology sector, specifically targeting supportive care in pediatric oncology. The market for therapies addressing chemotherapy-induced side effects is growing, driven by increasing cancer incidence and advancements in treatment regimens. The competitive landscape includes companies developing supportive care products and strategies to mitigate the adverse effects of cancer therapy. Fennec's focus on PEDMARK positions it to capture a share of this market by addressing a critical unmet need in preventing ototoxicity, a common and debilitating side effect of platinum-based chemotherapy in children.

Who Are FENC's Key Customers?

• Pediatric cancer patients undergoing platinum-based chemotherapy.
• Hospitals and cancer centers that treat pediatric cancer patients.
• Oncologists and other healthcare professionals who prescribe chemotherapy.

Company Profile

Fennec Pharmaceuticals Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Research Triangle Park, US. The company is led by CEO Jeffrey S. Hackman. FENC has traded publicly since 2017.

F-Score 5/9Financial Health

Fennec Pharmaceuticals Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 1.99 places it in the grey zone, a middle ground that warrants monitoring.

ROE -55%Key Financial Metrics

Return on equity for Fennec Pharmaceuticals Inc. stands at -55.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -11.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -2.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.98 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -2.4%, the inverse of the P/E and a quick read on earnings relative to price.

FENC Valuation & Market Position

With a $289M market cap, Fennec Pharmaceuticals Inc. sits in the micro-cap segment of the market. Relative to its peer group, FENC's quantitative score of 36/100 is below the peer average of 77/100.

FY2026 estForward Outlook

Wall Street analysts project Fennec Pharmaceuticals Inc. revenue of about $69.8M for fiscal 2026, with EPS near $0.25. The estimate reflects 5 contributing analysts.

Net buyingInsider Activity

Over the past six months, Fennec Pharmaceuticals Inc. insiders filed 30 SEC Form 4 transactions — 8 sales and 22 purchases. On net that is roughly 62K shares acquired (about $417K) — insiders putting money in tends to read as conviction.

FENC Financials

FENC Latest News

FENC Analyst Consensus

FENC MoonshotScore

Common Questions About FENC (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources